Table 1 Expression microarray studies used in the meta-analysis
| Â | Study [Reference] | Platform | Unique Genes Tested | Genes Sig Up (% of tested) | Genes Sig Down (% of tested) | Primary tumors | Distant Mets | GEO Accession |
|---|---|---|---|---|---|---|---|---|
1 | Bittner Breast [14] | HG U133 Plus 2.0 | 19079 | 33 (0.2%) | 0 (0%) | 327 | 9 | GSE2109 |
2 | Bittner Colon [14] | HG U133 Plus 2.0 | 19079 | 656 (3.4%) | 3938 (20.6%) | 330 | 43 | GSE2109 |
3 | Bittner Lung [14] | HG U133 Plus 2.0 | 19079 | 127 (0.6%) | 15 (0.1%) | 101 | 8 | GSE2109 |
4 | Bittner Ovarian [14] | HG U133 Plus 2.0 | 19079 | 494 (2.6%) | 131 (0.7%) | 166 | 75 | GSE2109 |
5 | Bittner Sarcoma [14] | HG U133 Plus 2.0 | 19079 | 4 (0%) | 1 (0%) | 42 | 10 | GSE2109 |
6 | Garber Lung [16] | Institutional cDNA microarray | 10723 | 9 (0.1%) | 57 (0.5%) | 61 | 6 | GSE3398 |
7 | Graudens Colon [17] | Institutional cDNA microarray | 6242 | 145 (2.3%) | 80 (1.3%) | 18 | 30 | GSE3964 |
8 | Haqq Melanoma [18] | Research Genetics cDNA microarray | 7344 | 420 (5.7%) | 639 (8.7%) | 6 | 19 | N/A |
9 | Holzbeierlein Prostate [19] | HG U95A-Av2 | 7820 | 11 (0.1%) | 295 (3.8%) | 40 | 9 | N/A |
10 | Jain Endocrine [20] | HG U95A-Av2 | 7820 | 14 (0.2%) | 229 (2.9%) | 8 | 17 | N/A |
11 | Lapointe Prostate [22] | Institutional cDNA microarray | 10021 | 1081 (10.8%) | 1219 (12.2%) | 62 | 9 | GSE3933 |
12 | LaTulippe Prostate [23] | HG U95A-Av2 | 7820 | 265 (3.4%) | 245 (3.1%) | 23 | 9 | N/A |
13 | Magee Prostate [26] | HG FL | 4564 | 35 (0.8%) | 18 (0.4%) | 8 | 3 | N/A |
14 | O'Donnell Oral [30] | HG U133A | 12427 | 1 (0%) | 28 (0.2%) | 22 | 5 | GSE2280 |
15 | Radvanyi Breast [31] | Custom cDNA microarray | 16133 | 548 (3.3%) | 85 (0.5%) | 47 | 7 | GSE1477 |
16 | Ramaswamy Multicancer [32] | HG FL, Hu35KsubA | 9064 | 556 (3.4%) | 301 (3.3%) | 10 | 4 | N/A |
17 | Segal Sarcoma [34] | HG U95A-Av2 | 7820 | 168 (2.1%) | 164 (2.1%) | 29 | 4 | N/A |
18 | Vanaja Prostate [38] | HG U133A, HG U133B | 17358 | 4 (0%) | 208 (1.2%) | 27 | 5 | N/A |